Ovarian cancer: recognition and initial management

New evidence

We found 51 new studies in a search for randomised control trials and RCTs published between 09 July 2012 and 01 June 2015. We also considered 8 additional studies identified by members of the Guideline Committee who originally worked on this guideline. We also considered 19 additional studies identified through stakeholder consultation.

Evidence identified in the previous evidence update (January 2013) was also considered. This included 14 studies identified by search.

From all sources, 91 studies were considered to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A: decision matrix for summaries and references for all new evidence considered in surveillance of this guideline.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline.

Views of stakeholders

Stakeholders commented on the decision not to update the guideline. Comments received from stakeholders at consultation expressed a need for NICE to review the recommendations on serum tumour markers for the diagnosis of ovarian cancer, in particular the role of HE4 and ROMA. Following stakeholder consultation it was agreed to update the guideline. See appendix 2 for stakeholders' comments and our responses.

See ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual' for more details on our consultation processes.

Date of next surveillance

Our next surveillance to decide whether the guideline should be updated is scheduled for 2017.

NICE Surveillance programme project team

Sarah Willett
Associate Director

Philip Alderson
Consultant Clinical Adviser

Katrina Sparrow
Technical Adviser

Saskia Cheyne
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.